The specific viral treatment for Covid 19 is under active investigation . At first there were hopes for drugs associated with other pathologies of which some kind of effectiveness has been seen against the SARS virus. But due to their adverse effects during the studies carried out, they are discouraged or used under strict control. This is the case with hydroxychloroquine , lopinavir / ritonavir and azithromycin .
Chloroquine , protagonist in the press due to the publicity of its miraculous effectiveness as a cure against Covid, caused a shortage of the drug used to combat lupus or inflammatory rheumatism.
For this reason, dexamethasone (corticosteroid) is currently included and lopinavir / ritonavir is excluded from the recommendations for its use as of July 15, 2020 in Catalonia.
There are few studies with remdesivir , an antiviral that blocks RNA polymerase, in Catalonia a clinical trial was carried out and the patients had a shorter recovery time compared to the placebo group. So the European Commission approved this treatment in adult and / or adolescent patients over 12 years of age and weighing at least 40 kg.
As a monoclonal antibody to the IL-6 receptor, tocilizumab . Its use is recommended intravenously to stop the inflammatory cascade with an effect on the need for artificial ventilation.
ADMISSION + PNEUMONIA
Asensio L. El renacimiento mediático de la cloroquina y la COVID-19. Rev Española de Comunicación en Salud [Internet]. 2020 [citado 1 ago 2020]; Suplemento 1, S350-S351. Dsiponible en:
M. Dante L, Fórmica N, Di Tommaso F, Aboy J, Chávez, et al. Taquicardias ventriculares polimórficas en el escenario de la pandemia por COVID-19. Hidroxicloroquina, Azitromicina y prolongación de QTc. Rev Electro y Arritmias [Internet]. 2020: 12: 12-23 [citado 29 jul 2020]. Disponible en:
[Last Updated: 12/08/2020]